^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Bavencio (avelumab)

    i
    Other names: MSB0010718C, PF-06834635, MSB-0010718C, COMPOUND 2055269, MSB 0010718C, PF06834635, PF 06834635
    Company:
    EMD Serono
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    4d
    ADAM: Adjuvant Avelumab in Merkel Cell Cancer (clinicaltrials.gov)
    P3, N=101, Active, not recruiting, University of Washington | Trial primary completion date: Apr 2026 --> Jan 2029
    Trial primary completion date
    |
    Bavencio (avelumab)
    7d
    Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study (clinicaltrials.gov)
    P3, N=654, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jul 2029 | Trial primary completion date: Jun 2026 --> Jul 2029
    Trial completion date • Trial primary completion date
    |
    IFNA1 (Interferon Alpha 1)
    |
    Bavencio (avelumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    8d
    Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors (clinicaltrials.gov)
    P1/2, N=23, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Jan 2027
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1) • MSH2 (MutS Homolog 2) • CDK12 (Cyclin dependent kinase 12) • ATRX (ATRX Chromatin Remodeler) • CHEK2 (Checkpoint kinase 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • CD4 (CD4 Molecule) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • FANCF (FA complementation group F) • FANCM (FA Complementation Group M) • FANCD2 (FA Complementation Group D2) • FANCE (FA Complementation Group E) • FANCC (FA Complementation Group C)
    |
    Bavencio (avelumab) • berzosertib (M6620)
    20d
    Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma. (PubMed, Cancer Med)
    This exploratory Bayesian reanalysis complements the interpretation of the JAVELIN Renal 101 trial and offers a probabilistic perspective beyond a dichotomous (i.e., significant/nonsignificant) interpretation.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    sunitinib • Bavencio (avelumab) • axitinib
    22d
    Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Apr 2026 --> Jan 2027 | Trial primary completion date: Apr 2026 --> Jan 2027
    Trial completion date • Trial primary completion date • Checkpoint inhibition • IO biomarker
    |
    ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    |
    Bavencio (avelumab) • tuvusertib (M1774) • lartesertib (M4076)
    23d
    Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (clinicaltrials.gov)
    P2, N=375, Active, not recruiting, BicycleTx Limited | Phase classification: P2/3 --> P2 | N=956 --> 375 | Trial completion date: Dec 2030 --> Mar 2028 | Trial primary completion date: Dec 2030 --> Mar 2028
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Bavencio (avelumab) • zelenectide pevedotin (BT8009)
    28d
    Clinical Feasibility of Platinum-Based Chemotherapy Followed by Avelumab Maintenance after Enfortumab Vedotin plus Pembrolizumab in Metastatic Urothelial Carcinoma: A case series. (PubMed, Chemotherapy)
    PBC is often considered as a subsequent treatment after EVP therapy, except in patients with FGFR gene alterations. PBC followed by avelumab maintenance therapy may represent a feasible subsequent treatment option for selected patients with mUC who achieve disease control after EVP therapy.
    Journal • PD(L)-1 Biomarker
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    Keytruda (pembrolizumab) • Bavencio (avelumab) • Padcev (enfortumab vedotin-ejfv)
    30d
    EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer (clinicaltrials.gov)
    P2, N=16, Completed, University College, London | Active, not recruiting --> Completed | N=130 --> 16 | Trial completion date: Oct 2024 --> Apr 2026
    Trial completion • Enrollment change • Trial completion date
    |
    Erbitux (cetuximab) • Bavencio (avelumab)
    1m
    Prognostic significance of early tumor shrinkage in metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based combination therapy. (PubMed, Int J Clin Oncol)
    Early tumor shrinkage was independently associated with the OS, suggesting its potential as a prognostic indicator in patients with mRCC treated with first-line ICI-based combination therapy.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CRP (C-reactive protein)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Lenvima (lenvatinib) • Bavencio (avelumab) • Cabometyx (cabozantinib tablet) • axitinib
    1m
    Drug Screening Using IMD in Bladder Cancer (clinicaltrials.gov)
    P1, N=18, Enrolling by invitation, Brigham and Women's Hospital | Not yet recruiting --> Enrolling by invitation | Trial completion date: Jul 2025 --> Aug 2028 | Trial primary completion date: Jul 2024 --> Jul 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • Bavencio (avelumab) • doxorubicin hydrochloride • Balversa (erdafitinib) • ifosfamide • vinblastine
    1m
    Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial GOIRC-02-2025 (2025-524077-16-00)
    P1/2, N=144, Not yet recruiting, G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica
    New P1/2 trial
    |
    Bavencio (avelumab)
    1m
    DISCUS: A Randomised Phase II Study Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer (2024-518244-20-01)
    P1/2, N=193, Active, not recruiting, Queen Mary University Of London | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Bavencio (avelumab)